SRPT — Sarepta Therapeutics Share News
0.000.00%
Last trade - 00:00- $1.88bn
- $1.94bn
- $2.20bn
Brief: Sarepta Therapeutics Says Douglas Ingram To Retire As CEO Of Sarepta
Brief: Sarepta Therapeutics Announces Fourth Quarter And Full-Year 2025 Financial Results
Brief: Sarepta Therapeutics Announces Commercial Launch Of Elevidys In Japan
US court revives Regenxbio patent lawsuit over muscular dystrophy treatment
Brief: Sarepta Therapeutics To Announce Fourth Quarter And Full-Year 2025 Financial Results
U.S. STOCKS ON THE MOVEx-IDEX Corp, Union Pacific, Qualcomm
U.S. STOCKS ON THE MOVE-CDW, Destiny Tech100, Avery Dennison
U.S. STOCKS ON THE MOVE-Bio-Techne, AbbVie, Johnson Controls
Sarepta rises on NZ regulatory nod to start Huntington's disease trial
Brief: Sarepta Therapeutics Announces Clinical Trial Application Approval For SRP-1005 In Huntington’s Disease
U.S. RESEARCH ROUNDUP-AMETEK, Stryker, Zimmer Biomet Holdings
U.S. STOCKS ON THE MOVE-Apple, Belite Bio, Bank of Marin Bancorp
U.S. STOCKS ON THE MOVE-US natgas companies
Sarepta jumps as data shows gene therapy slows decline in muscle‑wasting disease
U.S. STOCKS ON THE MOVE-Steel Dynamics, Eaton, CoreWeave
Sarepta's Duchenne gene therapy slows disease progression, three-year data shows (updated)
Sarepta rises as 3‑year data shows gene therapy slows decline in muscle‑wasting disease
Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows
U.S. STOCKS ON THE MOVE-Baker Hughes, Allied Gold Corp, MannKind Corp